

Build a bioanalytical strategy that will ensure speed and agility

The complexities of building a robust bioanalytical strategy for drug discovery and development can often be overwhelming and arduous. To build, execute, and optimize your strategy, it's important to work with a bioanalytical partner that has not only proven operational excellence across a range of traditional and cutting-edge technologies, but also the experience to support the unique needs of your development program.



- Gain access to a robust suite of mass spectrometry platforms for small and large molecule programs
- Achieve quality data for filing your IND, NDA, and CTA with speed
- Forecast technical issues or potential roadblocks that may cause delays
- Elucidate drug efficacy in pertinent spatial context down to the cellular level, for more efficient and effective drug candidate evaluation and selection
- Maximize the growth of your drug discovery and development investments



5M+ SAMPLES ANALYZED



150 BIOLOGICAL FLUIDS & TISSUES



48-HOURTURNAROUNDS
IN DISCOVERY

OFFERING	PLATFORMS	COMPOUNDS	REGULATIONS
Discovery	• LC-MS/MS	Small molecules	• GLP • VICH
Method development	• LC-HRMS	 Biomarkers 	• FDA • CVM
Method validation	 LC-Fluoresence 	 OGNs therapeutics 	• CDER • EMA
Sample analysis	detection	 Biologics 	• CBER • OECD
		• Endogenous	

<u>Contact us</u> to learn more about importing and exporting your biological samples.

